Key result
Between 2003 and 2012, US influenza antiviral expenditures totaled $3.74 billion for 32.8 million prescriptions, with use and expenditures correlating with influenza-like illness diagnoses.
Cross-Sectional
Yes
Influenza antivirals accounted for $3.74 billion in expenditures over a 10-year period in the US, with significant spikes during unforeseen pandemics like in 2009.
Rising antiviral expenditures and prescriptions may inform stewardship; leaves open optimal utilization and cost-effectiveness in routine care.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Suda et al. (2015) conducted a cross-sectional in Influenza. Influenza antivirals was evaluated on Influenza antiviral expenditures and correlation with ILI diagnoses. Between 2003 and 2012, US influenza antiviral expenditures totaled $3.74 billion for 32.8 million prescriptions, with use and expenditures correlating with influenza-like illness diagnoses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: